A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN13335, a Platelet-Derived Growth Factor-B Antagonist, in Healthy Adult Participants
Latest Information Update: 24 Mar 2025
At a glance
- Drugs REGN 13335 (Primary) ; REGN 13335 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 19 Mar 2025 Status changed from active, no longer recruiting to completed.
- 19 Nov 2024 Planned End Date changed from 12 Sep 2024 to 13 Feb 2025.
- 19 Nov 2024 Planned primary completion date changed from 12 Sep 2024 to 13 Feb 2025.